多模态影像组学在预测直肠癌免疫治疗相关蛋白表达中的研究进展
Research Progress of Multimodal Radiomics in Predicting Protein Expression Associated with Rectal Cancer Immunotherapy
DOI: 10.12677/acm.2025.1592663, PDF,    科研立项经费支持
作者: 翁圣涛, 张 颖:绍兴文理学院医学院,浙江 绍兴;卢增新*:绍兴市人民医院放射科(绍兴文理学院附属第一医院),浙江 绍兴
关键词: 多模态影像组学直肠癌免疫治疗蛋白Multimodal Imagemics Rectal Cancer Immunotheropy Protein
摘要: 近年来,多模态影像组学在直肠癌精准诊疗中展现出重要潜力,尤其在预测免疫治疗相关蛋白(如PD-L1、KI-67等)表达方面取得了显著进展。本文综述了基于CT、MRI及PET等多模态影像的组学特征提取与分析方法,探讨了其与免疫检查点蛋白表达的关联性。研究表明,影像组学可通过量化肿瘤异质性、功能代谢及灌注特征,无创预测关键生物标志物状态,为免疫治疗患者筛选提供新思路。然而,当前研究仍面临多中心数据标准化不足、模型泛化性有限等挑战。未来需结合深度学习与多组学数据,以进一步优化预测效能,推动个体化免疫治疗决策体系的建立。
Abstract: In recent years, multimodal radiomics has shown important potential in the precise diagnosis and treatment of rectal cancer, especially in predicting the expression of immunotherapy-related proteins (such as PD-L1, KI-67, etc.). In this paper, the omics feature extraction and analysis methods based on multimodal images such as CT, MRI and PET were reviewed, and their association with immune checkpoint protein expression was discussed. Studies have shown that radiomics can non-invasively predict the status of key biomarkers by quantifying tumor heterogeneity, functional metabolism and perfusion characteristics, providing new ideas for immunotherapy patient screening. However, current research still faces challenges such as insufficient standardization of multicenter data and limited generalization of models. In the future, it is necessary to combine deep learning and multi-omics data to further optimize the prediction efficiency and promote the establishment of an individualized immunotherapy decision-making system.
文章引用:翁圣涛, 张颖, 卢增新. 多模态影像组学在预测直肠癌免疫治疗相关蛋白表达中的研究进展[J]. 临床医学进展, 2025, 15(9): 1623-1630. https://doi.org/10.12677/acm.2025.1592663

参考文献

[1] 陈晨, 罗冬梅, 葛磊, 等. 结直肠癌肝转移患者预后列线图模型实证研究[J]. 中华肿瘤防治杂志, 2023, 30(22): 1362-1368.
[2] 申宇光, 王冬阳, 唐坚, 等. 结直肠癌早期筛查的最新进展[J]. 上海医学, 2023, 46(8): 515-518.
[3] 徐梦圆, 单天昊, 曾红梅. 2020年全球结肠癌和直肠癌发病死亡分析[J]. 江苏预防医学, 2023, 34(1): 12-16.
[4] Pennel, K., Dutton, L., Melissourgou-Syka, L., Roxburgh, C., Birch, J. and Edwards, J. (2024) Novel Radiation and Targeted Therapy Combinations for Improving Rectal Cancer Outcomes. Expert Reviews in Molecular Medicine, 26, e14. [Google Scholar] [CrossRef] [PubMed]
[5] Toda, S. and Kuroyanagi, H. (2013) Laparoscopic Surgery for Rectal Cancer: Current Status and Future Perspective. Asian Journal of Endoscopic Surgery, 7, 2-10. [Google Scholar] [CrossRef] [PubMed]
[6] Koukourakis, I.M., Kouloulias, V., Tiniakos, D., Georgakopoulos, I. and Zygogianni, A. (2023) Current Status of Locally Advanced Rectal Cancer Therapy and Future Prospects. Critical Reviews in Oncology/Hematology, 186, Article ID: 103992. [Google Scholar] [CrossRef] [PubMed]
[7] Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 7-33. [Google Scholar] [CrossRef] [PubMed]
[8] Kirkby, C.J., Gala de Pablo, J., Tinkler-Hundal, E., Wood, H.M., Evans, S.D. and West, N.P. (2021) Correction: Developing a Raman Spectroscopy-Based Tool to Stratify Patient Response to Pre-Operative Radiotherapy in Rectal Cancer. The Analyst, 146, 4401-4401. [Google Scholar] [CrossRef] [PubMed]
[9] Ell, P.J. (2006) The Contribution of PET/CT to Improved Patient Management. The British Journal of Radiology, 79, 32-36. [Google Scholar] [CrossRef] [PubMed]
[10] Tsukamoto, E. and Ochi, S. (2006) PET/CT Today: System and Its Impact on Cancer Diagnosis. Annals of Nuclear Medicine, 20, 255-267. [Google Scholar] [CrossRef] [PubMed]
[11] Lee, S.Y., Jeon, S.I., Jung, S., Chung, I.J. and Ahn, C. (2014) Targeted Multimodal Imaging Modalities. Advanced Drug Delivery Reviews, 76, 60-78. [Google Scholar] [CrossRef] [PubMed]
[12] Jennings, L.E. and Long, N.J. (2009) “Two Is Better than One”—Probes for Dual-Modality Molecular Imaging. Chemical Communications, No. 24, 3511-3524. [Google Scholar] [CrossRef] [PubMed]
[13] Coppola, F., Giannini, V., Gabelloni, M., Panic, J., Defeudis, A., Lo Monaco, S., et al. (2021) Radiomics and Magnetic Resonance Imaging of Rectal Cancer: From Engineering to Clinical Practice. Diagnostics, 11, Article No. 756. [Google Scholar] [CrossRef] [PubMed]
[14] Moreira, J.M., Santiago, I., Santinha, J., Figueiredo, N., Marias, K., Figueiredo, M., et al. (2019) Challenges and Promises of Radiomics for Rectal Cancer. Current Colorectal Cancer Reports, 15, 175-180. [Google Scholar] [CrossRef
[15] Liu, Z., Wang, S., Dong, D., Wei, J., Fang, C., Zhou, X., et al. (2019) The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges. Theranostics, 9, 1303-1322. [Google Scholar] [CrossRef] [PubMed]
[16] Romesser, P.B. and Cercek, A. (2024) Optimizing Rectal Cancer Treatment: A Path Towards Personalization. Annals of Oncology, 35, 831-835. [Google Scholar] [CrossRef] [PubMed]
[17] Sun, Y., Hu, P., Wang, J., Shen, L., Xia, F., Qing, G., et al. (2018) Radiomic Features of Pretreatment MRI Could Identify T Stage in Patients with Rectal Cancer: Preliminary Findings. Journal of Magnetic Resonance Imaging, 48, 615-621. [Google Scholar] [CrossRef
[18] Li, M., Zhang, J., Dan, Y., Yao, Y., Dai, W., Cai, G., et al. (2020) A Clinical-Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer. Journal of Translational Medicine, 18, Article No. 46. [Google Scholar] [CrossRef] [PubMed]
[19] Han, Y., Liu, D. and Li, L. (2020) PD-1/PD-L1 Pathway: Current Researches in Cancer. American Journal of Cancer Research, 10, 727-742.
[20] Incorvaia, L., Fanale, D., Badalamenti, G., Barraco, N., Bono, M., Corsini, L.R., et al. (2019) Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). Advances in Therapy, 36, 2600-2617. [Google Scholar] [CrossRef] [PubMed]
[21] Chen, L. and Han, X. (2015) Anti-PD-1/PD-L1 Therapy of Human Cancer: Past, Present, and Future. Journal of Clinical Investigation, 125, 3384-3391. [Google Scholar] [CrossRef] [PubMed]
[22] Riley, J.L. (2009) PD‐1 Signaling in Primary T Cells. Immunological Reviews, 229, 114-125. [Google Scholar] [CrossRef] [PubMed]
[23] Ribas, A. and Wolchok, J.D. (2018) Cancer Immunotherapy Using Checkpoint Blockade. Science, 359, 1350-1355. [Google Scholar] [CrossRef] [PubMed]
[24] Chen, D.S. and Mellman, I. (2017) Elements of Cancer Immunity and the Cancer-Immune Set Point. Nature, 541, 321-330. [Google Scholar] [CrossRef] [PubMed]
[25] Doroshow, D.B., Bhalla, S., Beasley, M.B., Sholl, L.M., Kerr, K.M., Gnjatic, S., et al. (2021) PD-L1 as a Biomarker of Response to Immune-Checkpoint Inhibitors. Nature Reviews Clinical Oncology, 18, 345-362. [Google Scholar] [CrossRef] [PubMed]
[26] Mok, T.S.K., Wu, Y., Kudaba, I., Kowalski, D.M., Cho, B.C., Turna, H.Z., et al. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, Pd-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830. [Google Scholar] [CrossRef] [PubMed]
[27] Zhang, X.Y., Zhu, H.T., Li, X.T., et al. (2022) A Prediction Model of Pathological Complete Response in Patients with Locally Advanced Rectal Cancer after PD-1 Antibody Combined with Total Neoadjuvant Chemoradiotherapy Based on MRI Radiomics. Chinese Journal of Gastrointestinal Surgery, 25, 228-234.
[28] Tian, X., Ma, A., Jia, Z., Ruzeaiti, B., Liang, G., Zeng, H., et al. (2025) MRI Radiomics Combined with Delta-Radiomics Model for Predicting Pathological Complete Response in Locally Advanced Rectal Cancer Patients after Neoadjuvant Chemoradiotherapy: A Multi-Institutional Study. Applied Radiation and Isotopes, 222, Article ID: 111842. [Google Scholar] [CrossRef] [PubMed]
[29] Wang, Y., Liu, Y., Guan, X., et al. (2025) Immunotherapy and Chemoradiotherapy for Mismatch Repair Proficient Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis. Radiotherapy and Oncology, 211, 111073. [Google Scholar] [CrossRef] [PubMed]
[30] Hayashi, H., Beppu, T., Sakamoto, Y., Miyamoto, Y., Yokoyama, N., Higashi, T., et al. (2015) Prognostic Value of Ki-67 Expression in Conversion Therapy for Colorectal Liver-Limited Metastases. American Journal of Cancer Research, 15, 1225-1233.
[31] Okumura, Y., Nishimura, R., Nakatsukasa, K., Yoshida, A., Masuda, N., Tanabe, M., et al. (2015) Change in Estrogen Receptor, HER2, and Ki-67 Status between Primary Breast Cancer and Ipsilateral Breast Cancer Tumor Recurrence. European Journal of Surgical Oncology (EJSO), 41, 548-552. [Google Scholar] [CrossRef] [PubMed]
[32] McDonnell, A.M., Nowak, A.K. and Lake, R.A. (2011) Contribution of the Immune System to the Chemotherapeutic Response. Seminars in Immunopathology, 33, 353-367. [Google Scholar] [CrossRef] [PubMed]
[33] Zitvogel, L., Galluzzi, L., Smyth, M.J. and Kroemer, G. (2013) Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance. Immunity, 39, 74-88. [Google Scholar] [CrossRef] [PubMed]
[34] Hiraoka, K., Miyamoto, M., Cho, Y., Suzuoki, M., Oshikiri, T., Nakakubo, Y., et al. (2006) Concurrent Infiltration by CD8+ T Cells and CD4+ T Cells Is a Favourable Prognostic Factor in Non-Small-Cell Lung Carcinoma. British Journal of Cancer, 94, 275-280. [Google Scholar] [CrossRef] [PubMed]
[35] Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., et al. (2013) Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin with Doxorubicin-Based Chemotherapy: BIG 02-98. Journal of Clinical Oncology, 31, 860-867. [Google Scholar] [CrossRef] [PubMed]
[36] Anitei, M., Zeitoun, G., Mlecnik, B., Marliot, F., Haicheur, N., Todosi, A., et al. (2014) Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer. Clinical Cancer Research, 20, 1891-1899. [Google Scholar] [CrossRef] [PubMed]
[37] Shinto, E., Hase, K., Hashiguchi, Y., Sekizawa, A., Ueno, H., Shikina, A., et al. (2014) CD8+ and FOXP3+ Tumor-Infiltrating T Cells before and after Chemoradiotherapy for Rectal Cancer. Annals of Surgical Oncology, 21, 414-421. [Google Scholar] [CrossRef] [PubMed]
[38] Imaizumi, K., Suzuki, T., Kojima, M., Shimomura, M., Sakuyama, N., Tsukada, Y., et al. (2019) Ki67 Expression and Localization of T Cells after Neoadjuvant Therapies as Reliable Predictive Markers in Rectal Cancer. Cancer Science, 111, 23-35. [Google Scholar] [CrossRef] [PubMed]
[39] Li, Q., Liu, J., Li, W., Qiu, M., Zhuo, X., You, Q., et al. (2024) Magnetic Resonance Imaging-Based Radiomics in Predicting the Expression of Ki-67, P53, and Epidermal Growth Factor Receptor in Rectal Cancer. Journal of Gastrointestinal Oncology, 15, 2088-2099. [Google Scholar] [CrossRef] [PubMed]
[40] Yao, X., Ao, W., Zhu, X., Tian, S., Han, X., Hu, J., et al. (2023) A Novel Radiomics Based on Multi-Parametric Magnetic Resonance Imaging for Predicting Ki-67 Expression in Rectal Cancer: A Multicenter Study. BMC Medical Imaging, 23, Article No. 168. [Google Scholar] [CrossRef] [PubMed]
[41] Meng, X., Xia, W., Xie, P., Zhang, R., Li, W., Wang, M., et al. (2018) Preoperative Radiomic Signature Based on Multiparametric Magnetic Resonance Imaging for Noninvasive Evaluation of Biological Characteristics in Rectal Cancer. European Radiology, 29, 3200-3209. [Google Scholar] [CrossRef] [PubMed]
[42] Le, C.C., Bennasroune, A., Collin, G., Hachet, C., Lehrter, V., Rioult, D., et al. (2020) LRP-1 Promotes Colon Cancer Cell Proliferation in 3D Collagen Matrices by Mediating DDR1 Endocytosis. Frontiers in Cell and Developmental Biology, 8, Article No. 412. [Google Scholar] [CrossRef] [PubMed]
[43] Schaue, D. and McBride, W.H. (2015) Opportunities and Challenges of Radiotherapy for Treating Cancer. Nature Reviews Clinical Oncology, 12, 527-540. [Google Scholar] [CrossRef] [PubMed]
[44] Lee, K.J., Ko, E.J., Park, Y., Park, S.S., Ju, E.J., Park, J., et al. (2020) A Novel Nanoparticle-Based Theranostic Agent Targeting LRP-1 Enhances the Efficacy of Neoadjuvant Radiotherapy in Colorectal Cancer. Biomaterials, 255, Article ID: 120151. [Google Scholar] [CrossRef] [PubMed]
[45] Yoshikawa, K., Shimada, M., Higashijima, J., et al. (2018) Ki-67 and Survivin as Predictive Factors for Rectal Cancer Treated with Preoperative Chemoradiotherapy. Anticancer Research, 38, 1735-1739.
[46] Li, Z., Huang, H., Wang, C., Zhao, Z., Ma, W., Wang, D., et al. (2022) DCE-MRI Radiomics Models Predicting the Expression of Radioresistant-Related Factors of LRP-1 and Survivin in Locally Advanced Rectal Cancer. Frontiers in Oncology, 12, Article ID: 881341. [Google Scholar] [CrossRef] [PubMed]
[47] Li, Z., Huang, H., Zhao, Z., Ma, W., Mao, H., Liu, F., et al. (2024) Development and Validation of a Nomogram Based on DCE-MRI Radiomics for Predicting Hypoxia-Inducible Factor 1α Expression in Locally Advanced Rectal Cancer. Academic Radiology, 31, 4923-4933. [Google Scholar] [CrossRef] [PubMed]
[48] Weisberg, E.M., Chu, L.C., Park, S., Yuille, A.L., Kinzler, K.W., Vogelstein, B., et al. (2020) Deep Lessons Learned: Radiology, Oncology, Pathology, and Computer Science Experts Unite around Artificial Intelligence to Strive for Earlier Pancreatic Cancer Diagnosis. Diagnostic and Interventional Imaging, 101, 111-115. [Google Scholar] [CrossRef] [PubMed]
[49] Hou, M. and Sun, J. (2021) Emerging Applications of Radiomics in Rectal Cancer: State of the Art and Future Perspectives. World Journal of Gastroenterology, 27, 3802-3814. [Google Scholar] [CrossRef] [PubMed]
[50] Kang, J., Rancati, T., Lee, S., Oh, J.H., Kerns, S.L., Scott, J.G., et al. (2018) Machine Learning and Radiogenomics: Lessons Learned and Future Directions. Frontiers in Oncology, 8, Article No. 228. [Google Scholar] [CrossRef] [PubMed]
[51] Duron, L., Savatovsky, J., Fournier, L. and Lecler, A. (2021) Can We Use Radiomics in Ultrasound Imaging? Impact of Preprocessing on Feature Repeatability. Diagnostic and Interventional Imaging, 102, 659-667. [Google Scholar] [CrossRef] [PubMed]